Interview with Bernadette Morris-Smith, Business Development Consultant,…
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Address: PO Box 475
Brookvale
NSW 2100
Tel: +61 (0)2 8968 9372
Web: http://www.transcrip-partners.com/
TranScrip Partners is a rapidly growing cutting-edge contract organisation that supports biopharmaceutical product development and life cycle management.
TranScrip Partners are strategic thinkers who do, and doers who think strategically.
Working for more than 50 companies across 4 continents, we challenge the traditional CRO model by championing medicinal products and overcoming the hurdles encountered from translational medicine to successful registration and market access.
Senior Partner Dr Sree Haran has also participated in this interview. TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would…
Dr Bernadette Morris-Smith has also participated in this interview TranScrip Partners is by now a well-established player in the UK but a new player in Asia Pacific. Would you begin…
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
See our Cookie Privacy Policy Here
